LACOG 0319
Quality of Life Assessment Study in Patients with Metastatic Head and Neck Neoplasia submitted to Immunotherapy in Brazil – LACOG 0319
Critérios de inclusão
Patients diagnosed with recurrent or metastatic epidermoid carcinoma of the head and neck region, whose disease has progressed up to 6 months from the beginning of the last cycle of systemic treatment with platinum, and who are using immunotherapy (nivolumab);
Patients with primary tumors of the pharynx (oro or hypopharynx), oral cavity and larynx;
Quer fazer parte do estudo?
Quero fazer parte do estudoPesquisas clínicas
Confira mais informações sobre o programa de pesquisa clínica do Grupo Oncoclínicas.
Saiba mais
